Suven Life Sciences receives second US patent

The US Patent office has granted Suven Life Sciences its second product patent.

The granted claims of the patent (product patent # US 7,317,035) include the class of selective Serotonin receptor affinity compounds discovered by Suven and being developed as therapeutic agents. According to the invention '035 patent disclosure, the compounds are useful in the treatment of neuro-degenarative disorders like Alzheimer's, Parkinson, Schizophrenia and Huntington's.

Suven has so far filed 29 product patent applications through PCT in 145 countries, out of which five product patents have been granted. Its research arm Suven Discovery Research has several other patent applications that have completed the administrative and technical diligence from the patent offices from major countries and would be granted shortly.

Suven has filed its first investigational new drug (IND) application with DCGI to conduct the clinical Phase-I study on their developmental candidate SUVN-502 and several candidates are in discovery pipeline undergoing GLP pre-clinical studies.

"We are very pleased by the issuance of this patent to Suven by US Patent Office for our drug candidates that are being developed for CNS disorders which targets a $18 billion potential market opportunity" says Suven's chief executive officer Venkat Jasti.